Takada, H.; Osawa, L.; Komiyama, Y.; Kato, R.; Nakakuki, N.; Muraoka, M.; Suzuki, Y.; Tatsumi, A.; Sato, M.; Takahashi, E.;
et al. Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports 2021, 4, 25.
https://doi.org/10.3390/reports4030025
AMA Style
Takada H, Osawa L, Komiyama Y, Kato R, Nakakuki N, Muraoka M, Suzuki Y, Tatsumi A, Sato M, Takahashi E,
et al. Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports. 2021; 4(3):25.
https://doi.org/10.3390/reports4030025
Chicago/Turabian Style
Takada, Hitomi, Leona Osawa, Yasuyuki Komiyama, Ryoh Kato, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Akihisa Tatsumi, Mitsuaki Sato, Ei Takahashi,
and et al. 2021. "Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma" Reports 4, no. 3: 25.
https://doi.org/10.3390/reports4030025
APA Style
Takada, H., Osawa, L., Komiyama, Y., Kato, R., Nakakuki, N., Muraoka, M., Suzuki, Y., Tatsumi, A., Sato, M., Takahashi, E., Takano, S., Fukasawa, M., Yamaguchi, T., Inoue, T., Maekawa, S., & Enomoto, N.
(2021). Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma. Reports, 4(3), 25.
https://doi.org/10.3390/reports4030025
